Search - tctmd.com

Displaying 1 - 20 of 155

Sort: Relevancy | Date

Presentation TCT 2025

TCT 1003: Clinical Effectiveness of Glucagon-like peptide-1 receptor agonists on Cardiovascular outcomes Post-PCI in Type 2 Diabetes patients: Findings from the TriNetX Database

Presenter: Aymen Ahmed

October 27, 2025

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

News Daily News

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

Yael L. Maxwell

August 14, 2025

HOPE Supports IV Alteplase in Late Window After Acute Ischemic Stroke

News Daily News

HOPE Supports IV Alteplase in Late Window After Acute Ischemic Stroke

August 11, 2025

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

Frail Older Patients With AF May Fare Better Switching to DOAC

News Daily News

Frail Older Patients With AF May Fare Better Switching to DOAC

August 05, 2025

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

HF Risks Stick Around Even When Ejection Fraction Improves

News Daily News

HF Risks Stick Around Even When Ejection Fraction Improves

August 01, 2025

Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe

News Industry News

Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe

August 01, 2025

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

TCTMD’s Top 10 Most Popular Stories for July 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2025

July 31, 2025

Heart Disease Treatment Costs $100 Billion per Year in the US

News Daily News

Heart Disease Treatment Costs $100 Billion per Year in the US

July 30, 2025

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

News Conference News SCCT 2025

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

Yael L. Maxwell

July 28, 2025

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

July 24, 2025

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

News Daily News

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

July 24, 2025

July 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

July 2025 Dispatch for the CV Team

July 24, 2025

AI-QCT Possibly Lessens Gap Between Ideal vs Actual Care for Patients at Risk of ASCVD

News Conference News SCCT 2025

AI-QCT Possibly Lessens Gap Between Ideal vs Actual Care for Patients at Risk of ASCVD

Yael L. Maxwell

July 22, 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

News Conference News SCCT 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Yael L. Maxwell

July 21, 2025

GLP-1s May Stave Off Dementia, EHR-Based Study Shows

News Daily News

GLP-1s May Stave Off Dementia, EHR-Based Study Shows

July 21, 2025

PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors

News Daily News

PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors

Michael O'Riordan

July 18, 2025

Clinicians Take Heed—High BP Merits Quick Action, Data Suggest

News Daily News

Clinicians Take Heed—High BP Merits Quick Action, Data Suggest

July 17, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.